Sep 29

Scientific

LBA 01 - Late-breaking Abstract Session

02:15pm - 03:30pm ET

Special Session

MODERATOR(S)

Beth Beadle, MD, PhD, FASTRO - Stanford University

Rachel Jimenez, MD, FASTRO - Massachusetts General Hospital

Credits

AMA PRA Category 1 Credits:

1.25

Rate This Session

Presentations

02:15pm - 02:25pm ET

TRIDENT: Phase 3 Trial of Tumor Treating Fields (TTFields) Therapy Concurrent with Temozolomide (TMZ) Radiochemotherapy Followed by Maintenance TMZ and TTFields for Newly Diagnosed Glioblastoma (ndGBM)

Speaker: Wenyin Shi, MD, PhD - Thomas Jefferson University, Philadelphia
02:25pm - 02:35pm ET

Alliance A071801 Phase III Trial Postoperative Single Fraction Stereotactic Radiosurgery (SRS) vs. Fractionated SRS (fSRS) for Resected Brain Metastasis

Speaker: Paul Brown, MD - Mayo Clinic, Rochester
02:35pm - 02:45pm ET

NRG-CC009: A Phase III Trial of Stereotactic Radiosurgery (SRS) vs. Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases from Small Cell Lung Cancer (SCLC)

Speaker: Chad Rusthoven, MD - University of Colorado School of Medicine, Aurora
02:45pm - 02:55pm ET

Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study

Speaker: Andrea Filippi, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
02:45pm - 02:55pm ET

Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study

Speaker: Andrea Filippi, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
02:55pm - 03:05pm ET

NRG-HN009 Randomized Phase II/III Trial of RT + Cisplatin Q3 Weeks vs RT + Cisplatin Weekly for Patients with Locoregionally Advanced SCCHN: p16-Negative Phase II Toxicity Results

Speaker: Paul Harari, MD, FASTRO - University of Wisconsin School of Medicine and Public Health, Madison
03:05pm - 03:15pm ET

A Phase II Trial of Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

Speaker: Silpa Raju-Salicki, MD - Washington University in St. Louis, St. Louis